Migraine

IV Fluid Confers No Significant Treatment Effect on Migraine Pain

IV Fluid Confers No Significant Treatment Effect on Migraine Pain

By

Investigators analyzed the effectiveness of IV fluid therapy in patients admitted to the emergency department with migraine.

Noninvasive Vagus Nerve Stimulation Effective for Episodic Migraines

Noninvasive Vagus Nerve Stimulation Effective for Episodic Migraines

By

Researchers studied the effectiveness of a hand-held device designed to electrically stimulate the vagus nerve in the neck through the skin to treat episodic migraines.

Cervical Dysfunction Needs Clarification to Identify Link With Headache

Cervical Dysfunction Needs Clarification to Identify Link With Headache

By

Future research is needed to determine whether cervical musculoskeletal dysfunction causes migraine or tension-type headache-related neck pain.

Ultrasound-Guided C2 Coblation May Be Effective for Cervicogenic Headache

Ultrasound-Guided C2 Coblation May Be Effective for Cervicogenic Headache

By

Treatment of cervicogenic headache with ultrasound-guided C2 nerve root coblation was associated with significant reductions in pain for at least 24 weeks.

IASP Updates Diagnosis Criteria for Chronic Primary Pain for ICD-11

IASP Updates Diagnosis Criteria for Chronic Primary Pain for ICD-11

By

The International Association for the Study of Pain updated its definitions for the diagnosis of chronic primary pain for the International Classification of Diseases, Eleventh Edition.

Researchers Identify Common Neurologic Manifestations in Fibromuscular Dysplasia

Researchers Identify Common Neurologic Manifestations in Fibromuscular Dysplasia

By

Common and rare neurologic manifestations associated with fibromuscular dysplasia include migraine-type headaches, tinnitus, ischemic stroke, and transient ischemic attack.

Type 2 Diabetes Risk Lower in Women With Active Migraine

Type 2 Diabetes Risk Lower in Women With Active Migraine

Women with active migraine have a lower risk for type 2 diabetes.

Migraine With Aura Linked to Increase in Incident A-Fib

Migraine With Aura Linked to Increase in Incident A-Fib

Migraine with aura is associated with an elevated risk for incident atrial fibrillation.

Ticagrelor May Be Less Effective for Migraine Relief Than Thienopyridines

Ticagrelor May Be Less Effective for Migraine Relief Than Thienopyridines

By

Investigators compared migraine response in participants taking ticagrelor vs participants taking a thienopyridine.

Headaches Identified as Potential Early Symptom of MS

Headaches Identified as Potential Early Symptom of MS

By

Researchers found a high frequency and a high prevalence of headaches at the onset of multiple sclerosis symptoms that decreased significantly 6 months post diagnosis.

Continuing Treatment With Galcanezumab Benefits Those Initially Unresponsive

Continuing Treatment With Galcanezumab Benefits Those Initially Unresponsive

By

For patients with episodic or chronic migraine who are initially unresponsive to galcanezumab, continued treatment may be associated with improvement.

Functional Nasal Surgery Can Improve Headache Symptoms

Functional Nasal Surgery Can Improve Headache Symptoms

For appropriately selected patients, functional nasal surgery is viable for improving headache symptoms.

External Trigeminal Nerve Stimulation May Alleviate Migraine Pain

External Trigeminal Nerve Stimulation May Alleviate Migraine Pain

By

A 1-hour treatment with external trigeminal nerve stimulation was found to alleviate pain in individuals with migraine without aura.

MFIQ Comprehensively Evaluates Migraine Intervention Outcomes

MFIQ Comprehensively Evaluates Migraine Intervention Outcomes

By

The MFIQ is a novel patient-reported outcome instrument developed as a quality measure of preventive therapies in adults with migraine.

Approved in Migraine, CGRP Antagonists Also Promising in Cluster Headache

Approved in Migraine, CGRP Antagonists Also Promising in Cluster Headache

By

Cluster headache and migraine are distinct primary headache disorders that are associated with substantial pain and disability.

Questionnaire Reliably Predicts Effect of Migraine on Work-Related Duties

Questionnaire Reliably Predicts Effect of Migraine on Work-Related Duties

By

The use of the HEADWORK questionnaire may provide insight into the effects of migraines on work productivity and lost workdays.

Topical Migraine Trigger Point Treatment as Effective as Injection

Topical Migraine Trigger Point Treatment as Effective as Injection

By

In a retrospective analysis, investigators assessed the effects of topical trigger point treatments on headache symptoms in patients with migraine.

Kinesiophobia May Be Associated With Greater Cutaneous Allodynia in Migraine

Kinesiophobia May Be Associated With Greater Cutaneous Allodynia in Migraine

By

Approximately half of patients with migraine have kinesiophobia, and the condition is associated with greater severity, not presence of cutaneous allodynia.

A Potential Biomarker for Predicting Antibody Treatment Efficacy in Migraine

A Potential Biomarker for Predicting Antibody Treatment Efficacy in Migraine

By

Researchers showed high migraine induction capabilities with calcitonin gene-related peptide (CGRP) in people with migraine who responded to erenumab treatment compared to data from previous CGRP provocation experiments.

Serum Vitamin D Levels and Risk for Migraine

Serum Vitamin D Levels and Risk for Migraine

By

Higher levels of serum 25-hydroxyvitamin D may be associated with lower risk for migraine headaches.

Migraine Associated With Self-Reported ADHD Symptoms in University Students

Migraine Associated With Self-Reported ADHD Symptoms in University Students

By

Migraine may be associated with self-reported attention deficit and hyperactivity disorder symptoms in university students.

Erenumab as a Therapy for Hard to Treat Episodic Migraine

Erenumab as a Therapy for Hard to Treat Episodic Migraine

By

Erenumab 140 mg is a well-tolerated and potentially effective preventive treatment for patients with episodic migraine, according to a phase 3b study.

Migraine Treatment in the ED: Overcoming Our Penchant for Opioids

Migraine Treatment in the ED: Overcoming Our Penchant for Opioids

By

There is significant evidence that opioids are not the right treatment of choice for migraine in the emergency department.

Genetic Risk Score Predicts Response to Triptans for Migraines Without Aura

Genetic Risk Score Predicts Response to Triptans for Migraines Without Aura

By

Genetic risk scores that focus on 2 single-nucleotide polymorphisms associated with migraines without aura might help predict patient response to triptan treatment.

Higher Headache Medication Use Not Associated With Higher Achievement Motivation

Higher Headache Medication Use Not Associated With Higher Achievement Motivation

By

Study showed no evidence for an effect of achievement motivation on the frequency of acute headache medication use.

Nonexpert Clinicians Lack Tools for Diagnosing Headache Disorders

Nonexpert Clinicians Lack Tools for Diagnosing Headache Disorders

By

There is a need for a tool in primary care to aid in managing and diagnosing headache disorders.

Assessing Headache Management Practices at Community Pharmacies

Assessing Headache Management Practices at Community Pharmacies

By

Counseling practices and headache management indicate the need for training and education of pharmacists in an Ethiopian city to better serve individuals with headache complaints.

Pain Acceptance May Reduce Headache-Related Disability in Migraine

Pain Acceptance May Reduce Headache-Related Disability in Migraine

By

Improved pain acceptance may be associated with a decrease in headache-related disability in patients with migraine.

IV Fluid Use Up, Narcotics Use Down in Patients With Migraine Admitted to ED

IV Fluid Use Up, Narcotics Use Down in Patients With Migraine Admitted to ED

By

A study looked at use of IV fluids, ketorolac, dexamethasone, and DRAs prochlorperazine/metoclopramide from 1999-2000 to 2014 in the treatment of patients with migraine admitted to the ED.

Lasmiditan NDA Submitted for Acute Treatment of Migraine

Lasmiditan NDA Submitted for Acute Treatment of Migraine

By

The NDA submission included data from two Phase 3 trials, SAMURAI and SPARTAN.

Sign Up for Free e-Newsletters